MK-6325 / Merck (MSD) - LARVOL DELTA

A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. (PubMed, Life Sci) - "HCV is one of the major health problems worldwide. Until the discovery of DAAs, HCV treatment faced many failures. DAAs target key functional machines of the virus life cycle and shut it down. NS3/4A protease is an important target and several drugs have been designed to inhibit its functions. There are several NS3/4A protease drugs approved by Food and Drug Administration (FDA). Unfortunately, the virus exhibits resistance against these drugs. This study is significant in elucidating that no one drug is able to treat different genotypes with the same efficiency. Therefore, treatment should be prescribed based on the HCV genotype."

Journal